Gilead and Galapagos's conscious uncoupling
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
Avenzo follows Bristol’s lead
The private group taps DualityBio for an EGFR x HER3 ADC.
CytomX shifts towards EpCAM
The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.
KAT6 catalysts to kick off 2025
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
ImmunityBio follows through in lung cancer
A new phase 3 study will test Anktiva in PD-(L)1-relapsed lung cancer.
FDA red and green lights: December 2024
Subcutaneous Opdivo joins Tecentriq Hybreza to round out 2024.
